MXPA04004492A - Indazolilpirrolotriazinas c-5 modificadas. - Google Patents

Indazolilpirrolotriazinas c-5 modificadas.

Info

Publication number
MXPA04004492A
MXPA04004492A MXPA04004492A MXPA04004492A MXPA04004492A MX PA04004492 A MXPA04004492 A MX PA04004492A MX PA04004492 A MXPA04004492 A MX PA04004492A MX PA04004492 A MXPA04004492 A MX PA04004492A MX PA04004492 A MXPA04004492 A MX PA04004492A
Authority
MX
Mexico
Prior art keywords
formula
compounds
useful
growth factor
factor receptors
Prior art date
Application number
MXPA04004492A
Other languages
English (en)
Inventor
D Vite Gregory
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MXPA04004492A publication Critical patent/MXPA04004492A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B41/00—After-treatment of mortars, concrete, artificial stone or ceramics; Treatment of natural stone
    • C04B41/009—After-treatment of mortars, concrete, artificial stone or ceramics; Treatment of natural stone characterised by the material treated
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B41/00—After-treatment of mortars, concrete, artificial stone or ceramics; Treatment of natural stone
    • C04B41/45—Coating or impregnating, e.g. injection in masonry, partial coating of green or fired ceramics, organic coating compositions for adhering together two concrete elements
    • C04B41/4584—Coating or impregnating of particulate or fibrous ceramic material
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B2111/00—Mortars, concrete or artificial stone or mixtures to prepare them, characterised by specific function, property or use
    • C04B2111/00474—Uses not provided for elsewhere in C04B2111/00
    • C04B2111/00793—Uses not provided for elsewhere in C04B2111/00 as filters or diaphragms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Ceramic Engineering (AREA)
  • Structural Engineering (AREA)
  • Materials Engineering (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Inks, Pencil-Leads, Or Crayons (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion proporciona compuestos de la formula I(ver formula I)y sales farmaceuticamente aceptables del mismo.Los compuestos de la formula I inhiben la actividad de la tirosina cinasa de los receptores del factor de crecimiento tales como HER1, HER2 y HER4 por ello haciendolos utiles como agentes antiproliferativos. Los compuestos de la formula I tambien son utiles para el tratamiento de otras enfermedades asociadas con las trayectorias de transdcucion de senal que operan a traves de los receptores del factor de crecimiento.
MXPA04004492A 2001-11-14 2004-05-12 Indazolilpirrolotriazinas c-5 modificadas. MXPA04004492A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33301401P 2001-11-14 2001-11-14

Publications (1)

Publication Number Publication Date
MXPA04004492A true MXPA04004492A (es) 2004-08-11

Family

ID=23300880

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04004492A MXPA04004492A (es) 2001-11-14 2004-05-12 Indazolilpirrolotriazinas c-5 modificadas.

Country Status (24)

Country Link
US (2) US6908916B2 (es)
EP (1) EP1446401B1 (es)
JP (1) JP4301440B2 (es)
KR (1) KR20050044441A (es)
CN (1) CN1615306A (es)
AR (1) AR037368A1 (es)
AT (1) ATE524462T1 (es)
BR (1) BR0214112A (es)
CA (1) CA2467068A1 (es)
ES (1) ES2370709T3 (es)
HR (1) HRP20040422A2 (es)
HU (1) HUP0402566A3 (es)
IL (1) IL161616A0 (es)
IS (1) IS7243A (es)
MX (1) MXPA04004492A (es)
NO (1) NO20041983L (es)
NZ (1) NZ533034A (es)
PE (1) PE20030712A1 (es)
PL (1) PL368909A1 (es)
RU (1) RU2004117549A (es)
TW (1) TW200300350A (es)
UY (1) UY27540A1 (es)
WO (1) WO2003042172A2 (es)
ZA (1) ZA200403694B (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6670357B2 (en) * 2000-11-17 2003-12-30 Bristol-Myers Squibb Company Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
US6867300B2 (en) 2000-11-17 2005-03-15 Bristol-Myers Squibb Company Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
TW200300350A (en) * 2001-11-14 2003-06-01 Bristol Myers Squibb Co C-5 modified indazolylpyrrolotriazines
ES2318122T3 (es) 2002-04-23 2009-05-01 Bristol-Myers Squibb Company Compuestos de aril cetona pirrolo-triazina utiles como inhibidores de quinasa.
US7388009B2 (en) 2002-04-23 2008-06-17 Bristol-Myers Squibb Company Heteroaryl-substituted pyrrolo-triazine compounds useful as kinase inhibitors
CA2483164C (en) * 2002-04-23 2011-06-07 Bristol-Myers Squibb Company Pyrrolo-triazine aniline compounds useful as kinase inhibitors
TW200401638A (en) * 2002-06-20 2004-02-01 Bristol Myers Squibb Co Heterocyclic inhibitors of kinases
TWI329112B (en) * 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
DK1767535T3 (da) 2002-08-23 2010-04-12 Sloan Kettering Inst Cancer Syntese af epothiloner, mellemprodukter deraf, analoge og deres anvendelse
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
TW200420565A (en) 2002-12-13 2004-10-16 Bristol Myers Squibb Co C-6 modified indazolylpyrrolotriazines
JP2006516653A (ja) 2003-02-05 2006-07-06 ブリストル−マイヤーズ　スクイブ　カンパニー キナーゼ阻害剤ピロロトリアジンの製造方法
US20060014741A1 (en) * 2003-12-12 2006-01-19 Dimarco John D Synthetic process, and crystalline forms of a pyrrolotriazine compound
US7102001B2 (en) 2003-12-12 2006-09-05 Bristol-Myers Squibb Company Process for preparing pyrrolotriazine
MY145634A (en) * 2003-12-29 2012-03-15 Bristol Myers Squibb Co Pyrrolotriazine compounds as kinase inhibitors
US7064203B2 (en) * 2003-12-29 2006-06-20 Bristol Myers Squibb Company Di-substituted pyrrolotriazine compounds
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
TW200538453A (en) 2004-04-26 2005-12-01 Bristol Myers Squibb Co Bicyclic heterocycles as kinase inhibitors
US7102002B2 (en) * 2004-06-16 2006-09-05 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US20050288290A1 (en) 2004-06-28 2005-12-29 Borzilleri Robert M Fused heterocyclic kinase inhibitors
US7432373B2 (en) 2004-06-28 2008-10-07 Bristol-Meyers Squibb Company Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
TW200600513A (en) 2004-06-30 2006-01-01 Bristol Myers Squibb Co A method for preparing pyrrolotriazine compounds
US7253167B2 (en) 2004-06-30 2007-08-07 Bristol-Myers Squibb Company Tricyclic-heteroaryl compounds useful as kinase inhibitors
US7102003B2 (en) * 2004-07-01 2006-09-05 Bristol-Myers Squibb Company Pyrrolotriazine compounds
US7504521B2 (en) 2004-08-05 2009-03-17 Bristol-Myers Squibb Co. Methods for the preparation of pyrrolotriazine compounds
PE20060421A1 (es) 2004-08-12 2006-06-01 Bristol Myers Squibb Co Procedimiento para preparar un compuesto de pirrolotriazina anilina como inhibidores de cinasa
US7151176B2 (en) 2004-10-21 2006-12-19 Bristol-Myers Squibb Company Pyrrolotriazine compounds
TW200635927A (en) * 2004-12-22 2006-10-16 Bristol Myers Squibb Co Synthetic process
US7358256B2 (en) 2005-03-28 2008-04-15 Bristol-Myers Squibb Company ATP competitive kinase inhibitors
US7534882B2 (en) 2005-04-06 2009-05-19 Bristol-Myers Squibb Company Method for preparing pyrrolotriazine compounds via in situ amination of pyrroles
US7547782B2 (en) 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
US7514435B2 (en) * 2005-11-18 2009-04-07 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7348325B2 (en) 2005-11-30 2008-03-25 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
PE20070855A1 (es) * 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
US8143393B2 (en) 2005-12-02 2012-03-27 Bayer Healthcare Llc Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
US8063208B2 (en) 2006-02-16 2011-11-22 Bristol-Myers Squibb Company Crystalline forms of (3R,4R)-4-amino-1-[[4-[(3-methoxyphenyl)amino]pyrrolo[2,1-f][1,2,4]triazin-5-yl]methyl]piperidin-3-ol
DE102006030479A1 (de) * 2006-07-01 2008-03-20 Merck Patent Gmbh Indazolderivate
US8071779B2 (en) 2006-12-18 2011-12-06 Inspire Pharmaceuticals, Inc. Cytoskeletal active rho kinase inhibitor compounds, composition and use
ES2539620T3 (es) 2008-12-19 2015-07-02 Cephalon, Inc. Pirrolotriazina como inhibidor de ALK y de JAK2
US20120149902A1 (en) * 2009-07-28 2012-06-14 Ube Industries, Ltd. Pyrrolo[2,3-d]pyrimidine derivative
CN102627647A (zh) * 2012-03-20 2012-08-08 南京药石药物研发有限公司 4-氯-5-甲基-1H-吡咯并[2,1-f][1,2,4]三嗪的合成方法
US9447105B2 (en) 2013-01-24 2016-09-20 Council Of Scientific & Industrial Research Triazine compounds and a process for preparation thereof
CN105979950A (zh) 2013-10-11 2016-09-28 百时美施贵宝公司 吡咯并三嗪激酶抑制剂
WO2015081783A1 (zh) * 2013-12-06 2015-06-11 江苏奥赛康药业股份有限公司 吡咯并[2,1-f][1,2,4]三嗪类衍生物及其制备方法和用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4908056A (en) 1986-04-25 1990-03-13 E. I. Du Pont De Nemours And Company Heterocyclic acyl sulfonamides
ATE243697T1 (de) 1995-12-08 2003-07-15 Pfizer Substitutierte heterozyclische derivate als crf antagonisten
DE69736711T2 (de) 1996-08-28 2007-09-20 Pfizer Inc. Substituierte 6,5-heterobicyclische-derivate
RU2331640C2 (ru) * 1999-05-21 2008-08-20 Бристол-Маерс Сквибб Ко. Пирролтриазиновые ингибиторы киназ
US6787545B1 (en) 1999-08-23 2004-09-07 Shiongi & Co., Ltd. Pyrrolotriazine derivatives having spla2-inhibitory activities
US6867300B2 (en) * 2000-11-17 2005-03-15 Bristol-Myers Squibb Company Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
US20040082585A1 (en) * 2001-10-03 2004-04-29 Pharmacia Corporation Prodrugs of substituted polycyclic compounds useful for selective inhibition of the coagulation cascade
TW200300350A (en) * 2001-11-14 2003-06-01 Bristol Myers Squibb Co C-5 modified indazolylpyrrolotriazines
ES2318122T3 (es) * 2002-04-23 2009-05-01 Bristol-Myers Squibb Company Compuestos de aril cetona pirrolo-triazina utiles como inhibidores de quinasa.
TW200400034A (en) * 2002-05-20 2004-01-01 Bristol Myers Squibb Co Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors
TWI329112B (en) * 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases

Also Published As

Publication number Publication date
HUP0402566A3 (en) 2009-01-28
JP4301440B2 (ja) 2009-07-22
NO20041983L (no) 2004-06-24
HUP0402566A2 (hu) 2005-03-29
CA2467068A1 (en) 2003-05-22
AR037368A1 (es) 2004-11-03
US6908916B2 (en) 2005-06-21
IS7243A (is) 2004-04-30
NO20041983D0 (no) 2004-05-13
ATE524462T1 (de) 2011-09-15
EP1446401B1 (en) 2011-09-14
ES2370709T3 (es) 2011-12-22
RU2004117549A (ru) 2006-01-10
WO2003042172A2 (en) 2003-05-22
CN1615306A (zh) 2005-05-11
HRP20040422A2 (en) 2005-04-30
EP1446401A2 (en) 2004-08-18
US20050209235A1 (en) 2005-09-22
BR0214112A (pt) 2004-09-14
WO2003042172A3 (en) 2004-01-29
US20030186983A1 (en) 2003-10-02
EP1446401A4 (en) 2006-04-12
TW200300350A (en) 2003-06-01
UY27540A1 (es) 2003-07-31
NZ533034A (en) 2004-11-26
ZA200403694B (en) 2006-06-28
KR20050044441A (ko) 2005-05-12
JP2005509030A (ja) 2005-04-07
PE20030712A1 (es) 2003-08-21
IL161616A0 (en) 2004-09-27
PL368909A1 (en) 2005-04-04

Similar Documents

Publication Publication Date Title
MXPA04004492A (es) Indazolilpirrolotriazinas c-5 modificadas.
TW200420565A (en) C-6 modified indazolylpyrrolotriazines
UA89038C2 (en) Pyrrolotriazine compounds as kinase inhibitors
EP1773791A4 (en) PYRROLOTRIAZINVERBINDUNGEN
MY134848A (en) Pyrrolo[2,1-f] [1,2,4] triazine inhibitors of kinases
WO2004001059A3 (en) Heterocyclic inhibitors of kinases
MY128370A (en) Pyrrolotriazane inhibitors of kinases
WO2006007378A3 (en) Pyrrolotriazine kinase inhibitors
WO2005065266A8 (en) Di-substituted pyrrolotriazine compounds
WO2004009542A3 (en) Process for preparing certain pyrrolotriazine compounds
MY133667A (en) Quinazoline ditosylate salt compounds
TNSN05045A1 (en) Indole or benzimidazole derivatives for modulating ikappab kinase
MXPA04004107A (es) Moleculas pequenas para el tratamiento del crecimiento celular anormal.
MXPA05010621A (es) Pirimidinonas sustituidas.
NO20063324L (no) 3-cyano-kinolinderivater med antiproliferativ aktivitet
WO2005058245A3 (en) Synthetic process
MXPA04005809A (es) Inhibidores de proteinas quinasas.
TW200635927A (en) Synthetic process
UA90659C2 (ru) Аналоги хиназолина как ингибиторы рецепторных тирозинкиназ
WO2006135796A3 (en) Crystalline forms of a pyrrolotriazine compound
DE602006004976D1 (de) Kompetitive atp-kinasehemmer